News
SEC Davao reminds corporations to comply with the 2025 deadlines for online submission of Annual Financial Statements (AFS) ...
2d
Inquirer Business on MSNPSE inks deal to buy MUFG shares in PDSThe Stock Exchange Inc. (PSE) will buy an additional 0.2-percent stake in the country’s bond trading platform, moving closer ...
Several member banks of the Bankers Association of the Philippines (BAP) plan to acquire up to a 49-percent stake in the ...
In a widely expected move, the Trump administration will not defend a Biden-era Securities and Exchange Commission (SEC) ...
5d
Philstar.com on MSNCemex Philippines rebrands to Concreat HoldingsCemex Holdings Philippines has completed its rebranding initiative, with the company now officially Concreat Holdings ...
7d
GMA Network on MSNCemex Philippines officially rebrands to ConcreatConsunji-led Cemex Holdings Philippines has rebranded to Concreat Holdings Philippines Inc., after securing the go-ahead from ...
Zevra Therapeutics (ZVRA) has filed its definitive proxy statement with the U.S. Securities and Exchange Commission in connection with the ...
In a wiy expected move, the Trump administration will not defend a Biden-era Securities and Exchange Commission (SEC) climate disclosure rule under challenge by a slew of […] ...
However, on April 1, TMTG did reregister for sale shares belonging to Trump and several other shareholders, according to a filing with the U.S. Securities and Exchange Commission (SEC).
Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates
Rezdiffra™ (resmetirom) net sales of $137.3 million As of March 31, 2025, more than 17,000 patients on Rezdiffra Two-year compensated MASH cirrhosis (F4c) data from MAESTRO-NAFLD-1 trial selected as ...
Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing ...
Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat cancers and viruses, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results